CommercialAdministrativeMedium impact
06.02.32d, Multigene Expression Assays for Predicting Recurrence in Colon Cancer (Independence Administrators)
Independence Blue Cross·Oncology, Gastroenterology, General Surgery·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued their medical policy for multigene expression assays used to predict colon cancer recurrence. This is a policy reissuance rather than a content change, but billing teams should verify current coverage criteria and billing requirements for these genetic tests.
Action Required
By March 5, 2025: Billing team should review the updated policy document at the provided URL to verify current coverage criteria, prior authorization requirements, and billing guidelines for multigene expression assays in colon cancer patients. Ensure billing staff are aware of any specific documentation requirements for these genetic tests.